Solventum Corp.
- SOLV ยท NYSE
- Surgical & Medical Instruments & Apparatus
- Eagan, MN
- 10,000 employees
- CIK 0001964738
Updated from SEC filings through
Top things to know
Executives
- Bryan C. Hanson Chief Executive Officer 4, 2026-09-03
- Wayde D. McMillan Chief Financial Officer 4, 2026-05-15
- Wayde McMillan Executive Vice President and Chief Financial Officer (Mr. McMillan is the Principal Financial Officer and has been duly authorized to sign on behalf of the Regi 10-K, 2026-02-27
- Neil Zieselman Senior Vice President, Controller and Chief Accounting Officer 8-K, 2026-07-20
- Amy Landucci Chief Information Officer 4, 2026-05-15
- Marcela A. Kirberger Chief Legal Affairs Officer 4, 2026-05-15
What leadership is saying
“Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover; we expect to be near the top end of our full-year organic sales growth range, and are raising our full-year adjusted earnings per share outlook”
Earnings press release (8-K Ex. 99.1), filed November 5, 2026
Solventum Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Eagan, MN. It trades as SOLV on NYSE. Revenue was $8.3B in the fiscal year ending December 31, 2025, +0.9% from the year before. It reported about 10,000 employees. Bryan C. Hanson is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $8.3B 10-K, 2026-02-27 | $8.3B 10-K, 2026-02-27 | $8.2B 10-K, 2026-02-27 | $8.1B 10-K, 2025-02-28 |
| Operating income | $2.2B 10-K, 2026-02-27 | $1.0B 10-K, 2026-02-27 | $1.7B 10-K, 2026-02-27 | $1.7B 10-K, 2025-02-28 |
| SG&A | $3.1B 10-K, 2026-02-27 | $2.8B 10-K, 2026-02-27 | $2.3B 10-K, 2026-02-27 | $2.2B 10-K, 2025-02-28 |
| Net income | $1.6B 10-K, 2026-02-27 | $479M 10-K, 2026-02-27 | $1.3B 10-K, 2026-02-27 | $1.3B 10-K, 2025-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Bryan C. Hanson | Chief Executive Officer | 4, 2026-09-03 |
| Wayde D. McMillan | Chief Financial Officer | 4, 2026-05-15 |
| Wayde McMillan Chief Financial Officer, Solventum | Executive Vice President and Chief Financial Officer (Mr. McMillan is the Principal Financial Officer and has been duly authorized to sign on behalf of the Regi | 10-K, 2026-02-27 |
| Neil Zieselman Senior Vice President, Controller and Chief Accounting Officer at Solventum | Senior Vice President, Controller and Chief Accounting Officer | 8-K, 2026-07-20 |
| Amy Landucci Chief Information and Digital Officer | Chief Information Officer | 4, 2026-05-15 |
| Marcela A. Kirberger | Chief Legal Affairs Officer | 4, 2026-05-15 |
| Mary T. Wilcox | Chief Accounting Officer | 4, 2026-05-15 |
| Paul S. Harrington | Chief Supply Chain Officer | 4, 2026-05-15 |
| Tammy L. Gomez | Chief Human Resources Officer | 4, 2026-05-15 |
| Heather Knight Chief Commercial Officer, Solventum | Chief Commercial Officer | 4, 2026-03-09 |
| Paul Harrington Chief Supply Chain Officer | Chief Supply Chain Officer | 10-K, 2026-02-27 |
| Tammy Gomez Chief Human Resources Officer, Solventum | Chief Human Resources Officer | 10-K, 2026-02-27 |
| Marcela Kirberger | Chief Corporate & Legal Affairs Officer | 10-K, 2026-02-27 |
| Mary Wilcox | Senior Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer) | 10-K, 2026-02-27 |
| Neil Craig Zieselman | SVP, Controller & CAO | 4, 2026-08-18 |
What Solventum Corp does
Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 169.7 million (as of October 31, 2026) | 10-Q, November 5, 2026 |
|---|---|---|
| Public float | $13.1B (as of June 30, 2025) | 10-K, February 27, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 5, 2026 |
| Latest proxy statement | Meeting December 31, 2025 (filed March 27, 2026) | DEF 14A, March 27, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Minneapolis, Minnesota) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| March 10, 2026 | Amy McBride Wendell Director | Buy | 1,475 | $100K | Form 4, March 11, 2026 |
Recent 8-K events
- 8-K filed 2026-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-07-20
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-05
- Item 8.01 Other events
- 8-K filed 2026-05-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-20
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-24
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Solventum Corp
- What does Solventum Corp do?
- In its own words, from Item 1 of its 10-K: "Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise."
- What is Solventum Corp's revenue?
- $8.3B for the fiscal year ending December 31, 2025, from its 10-K filed February 27, 2026.
- Is Solventum Corp profitable?
- Solventum Corp reported net income of $1.6B for the fiscal year ending December 31, 2025.
- How many employees does Solventum Corp have?
- About 10,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Solventum Corp?
- Bryan C. Hanson, Chief Executive Officer, as named in a 4 filed September 3, 2026.
- Who is the CFO of Solventum Corp?
- Wayde D. McMillan, Chief Financial Officer, as named in a 4 filed May 15, 2026.
- Where is Solventum Corp headquartered?
- Eagan, MN.
- What is Solventum Corp's stock ticker?
- SOLV on NYSE.
- What industry is Solventum Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Solventum Corp's website?
- solventum.com. Investor relations: https://investors.solventum.com/.
- When does Solventum Corp report earnings next?
- February 5, 2027. Source: estimate_8k_pattern.
- Is Solventum Corp a public company?
- Yes. Solventum Corp files with the SEC under CIK 0001964738 and trades as SOLV.
- Who audits Solventum Corp?
- PricewaterhouseCoopers LLP, Minneapolis, Minnesota, as named in its latest annual report (10-K).
- How many shares of Solventum Corp are outstanding?
- 169.7 million shares as of October 31, 2026, from its 10-Q filed November 5, 2026.
- What is Solventum Corp's public float?
- $13.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 27, 2026.
- How many business segments does Solventum Corp report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 5, 2026.
- When is Solventum Corp's annual shareholder meeting?
- December 31, 2025, per its proxy statement (DEF 14A) filed March 27, 2026.
- Have Solventum Corp insiders traded stock recently?
- Since March 10, 2026, officers and directors reported 0 open-market sales and 1 purchase worth about $100K on Forms 4 and 5. The most recent: Amy McBride Wendell (Director) bought 1,475 shares on March 10, 2026.